Chimerna Therapeutics, Inc.
- UEI
- JMH6UEKMAE65
- CAGE
- 8CYP3
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- chimerna.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Chimerna Therapeutics, Inc.
Chimerna Therapeutics, Inc. is a biotechnology company registered in SAM.gov, located in New York, NY, that specializes in advanced RNA research and therapeutic technologies. The company focuses on developing innovative circular RNA (circRNA) technologies, with a particular emphasis on creating novel approaches for RNA synthesis, delivery, and therapeutic applications. Chimerna has developed proprietary technologies like the "Tornado" platform for expressing RNAs as circles, which enables high-level RNA production and enhanced stability compared to conventional linear RNA methods.
Through federal grant awards, Chimerna Therapeutics has consistently secured funding from multiple National Institutes of Health (NIH) agencies, including the National Institute of General Medical Sciences, National Center for Advancing Translational Sciences, National Institute of Neurological Disorders and Stroke, and National Institute of Diabetes and Digestive and Kidney Diseases. Their grant-funded research has concentrated on developing advanced circular RNA technologies with potential therapeutic applications across various medical domains, such as addressing neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) and Parkinson's disease, exploring iron homeostasis regulation, and creating innovative RNA manufacturing platforms. Specific research projects have included developing yeast-based circRNA manufacturing platforms, creating circular RNA aptamers to regulate cellular processes, optimizing RNA synthesis and labeling techniques, and exploring methods to improve RNA therapeutic delivery by enhancing endosomal escape and cellular uptake mechanisms.
Quick answers
What is Chimerna Therapeutics, Inc.'s UEI?
Chimerna Therapeutics, Inc.'s Unique Entity ID (UEI) in SAM.gov is JMH6UEKMAE65.
What is Chimerna Therapeutics, Inc.'s CAGE code?
Chimerna Therapeutics, Inc.'s CAGE code is 8CYP3.
What is Chimerna Therapeutics, Inc.'s primary NAICS code?
Chimerna Therapeutics, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Is Chimerna Therapeutics, Inc. registered in SAM.gov?
Chimerna Therapeutics, Inc.'s SAM.gov registration expired on February 3, 2026.
What is Chimerna Therapeutics, Inc.'s most recent federal award?
Chimerna Therapeutics, Inc.'s most recent federal grant award is Synthetic biology approaches for BIO-orthogonal labeling of circular rnas - summary the key challenges for RNA… (R43GM157885), from National Institute of General Medical Sciences, on February 1, 2025.
On GovTribe
See Chimerna Therapeutics, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors